Prostate Cancer covers the etiology, pathophysiology, diagnosis, management and treatment of early and advanced prostate cancer.

Features:

• The pathology and etiology of prostate cancer
• Molecular mechanisms of prostate carcinogenesis
• Clinical diagnosis and staging of prostate cancer
• Treatment of early stage prostate cancer
• Treatment of locally advanced and metastatic prostate cancer

Contents

Introduction

1. Prostate cancer: A historical introduction
2. Genetic epidemiology
3. Risk factors for prostate cancer: diet and lifestyle studies
4. Molecular epidemiology of prostate cancer
5. Applications of gene array technology to prostate cancer
6. Topographic anatomy of the prostate, seminal vesicles, vas deferens, and ejaculatory ducts
7. Prostate physiology and function
8. Neuroanatomy and neuroregulation
9. Androgens and the androgen receptor in normal prostate
10. Regulation of prostate growth

Pathology of Prostate Cancer

11. Histopathology of prostate cancer and pathologic staging
12. Pre-malignant and atypical lesions
13. Pathologic characteristics of soft tissue and osseous metastases
14. Non-adenocarcinomatous neoplasms of the prostate
15. Neuroendocrine differentiation in prostate cancer
16. New concepts in the molecular pathology of prostate cancer
17. Cytogenetics and molecular heterogeneitity

Etiology of Prostate Cancer

18. Concepts in etiology of prostate cancer
19. Diet and obesity in prostate carcinogenesis
20. Chemoprevention of prostate cancer: Concepts and evidence
21. Molecular aspects of chemoprevention of prostate cancer
22. Androgen replacement in the aging male and prostate cancer
23. Vitamin D, retinoids, and prostate cancer

Molecular Mechanisms of Prostate Carcinogenesis

24. Mechanisms of prostate cancer progression
25. Case control and linkage studies in familial and hereditary prostate cancer
26. Prostate Cancer Stem Cells
27. Rationale for molecular biomarkers of prostate cancer
28. Molecular biology of serum biomarkers for prostate cancer
29. Molecular biology of tissue biomarkers for prostate cancer
30. Biologic response modifiers and prostate cancer
31. Cell adhesion and prostate cancer
32. Apoptosis and prostate cancer
33. Cellular proliferation and senescence in prostate cancer
34. Angiogenesis and prostate cancer
35. Endothelin and prostate cancer
36. Mechanisms of androgen resistance
37. Knockout models of prostate carcinogenesis
38. Molecular mechanisms of prostate cancer metastases
39. Molecular concepts of emerging strategies for prostate cancer treatment

Clinical Diagnosis and Staging of Prostate Cancer

40. New concepts in the early detection of prostate cancer
41. Screening for prostate cancer: The ERSPC Study
42. Screening for prostate cancer and its effect on mortality: The TYROL Study Endothelin and prostate cancer
43. Lessons from the Prostate Cancer Awareness Week Program and PLCO Study
44. Clinical staging of prostate cancer: An overview
45. TNM and IUCC staging of prostate cancer
46. PSA: Practical applications and future prospects
47. Clinical applications of PSA isoforms
48. Radiographic anatomy of the prostate
49. Transrectal and transperineal ultrasound-guided prostate biopsy
50. Multivariate models for decreasing unnecessary biopsies
51. MR Imaging (MRI) and MR Spectroscopic Imaging (MRSI) in the diagnosis and staging of prostate cancer.
52. Radioimmunoscintography for imaging prostate cancer
53. Clinical applications of immunoscintigraphy for prostate cancer
54. Future directions in the imaging of prostate cancer
55. Local therapy for prostate-specific antigen recurrence after definitive treatment.
56. Multivariate models for predicting pathological stage
57. Multivariate models for predicting biochemical recurrence after definitive local therapy
58. Coping with a diagnosis of prostate cancer: A patient's perspective
59. Clinical interpretation of prostate cancer biopsy reports
60. Urine-based diagnostic tests for prostate
61. Diagnostic tests for prostate cancer: Future directions

Treatment of Early Stage Prostate Cancer

62. Choosing prostate cancer treatment: The clinician as patient
63. The role of the primary care professional in the care of the prostate cancer patient
64. Natural history and expectant management of prostate cancer
65. Clinical trials comparing expectant management to definitive treatment of prostate cancer (PIVOT, Holmberg, PROTECT, etc.)
66. Complimentary and alternative medicine in the prevention and treatment of prostate cancer
67. Mortality trends in prostate cancer
68. Preservation of sexual function in prostate cancer treatment
69. Quality of life instruments for prostate cancer
70. Comparison of treatment modalities for prostate cancer by quality of life instruments
71. Decision tools in patient selection for radical prostatectomy
72. Anatomical considerations of radical prosptatectomy
73. Radical retropubic prostatectomy
74. Radical retropubic prostatectomy: contemporary modifications
75. The role of lymph node dissection in radical prostatectomy
76. Management of biochemical recurrence following radical prostatectomy
77. Radical perineal prostatectomy
78. Laparoscopic and robotic radical prostatectomy
79. Vattikuti Institute Prostatectomy
80. Initial management of high risk early stage prostate cancer: surgery
81. Management of short and long term complications of radical prostatectomy
82. External beam radiotherapy for the treatment of prostate cancer
83. Brachytherapy for the treatment of prostate cancer
84. HDR monotherapy for prostate cancer
85. Magnetic resonance image-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate
86. Hyperthermia for treatment of localized prostate cancer
87. Initial management of high risk early stage prostate cancer: radiation
88. Management of biochemical recurrence following radiation therapy
89. Cryotherapy as primary therapy for prostate cancer
90. Cryotherapy as salvage therapy for prostate cancer
91. Androgen deprivation for the treatment of prostate cancer: General principles
92. Neoadjuvant and adjuvant hormonal therapies for prostate cancer: data review and patient perspectives
93. Controversies in hormone treatment for prostate cancer
94. Androgen deprivation for prostate cancer: Future directions
95. Rehabilitation of urinary continence following definitive treatment of local prostate cancer
96. Rehabilitation of sexual function following definitive treatment of local prostate cancer
97. The limitations ofevidence based comparisons of treatment for localized prostate cancer

Treatment of Locally Advanced and Metastatic Prostate Cancer

98. Hormone therapy for prostate cancer: Optimization and timing
99. Intermittent hormone therapy for prostate cancer
100. Anti-androgen withdrawal syndrome: Identification and treatment
101. Chemotherapy for advanced prostate cancer
102. Radiotherapy for the treatment of locally advanced and metastatic prostate cancer
103. Radionucleotides for the treatment of metastatic prostate cancer
104. Use of bis-phosphonates in the management of osseous metastases
105. Treatment of non-adenocarcinomatous and small cell neoplasms of the prostate
106. Multi-modal therapy for advanced prostate cancer
107. Management of complications of advanced prostate cancer
108. Principles of palliative care and psychosocial support of the metastatic prostate cancer patient
109. Future directions for treatment of advanced prostate cancer: Gene therapy and other novel modalities
110. Prostate cancer and the media: Raising public awareness

Index

click here to see books • videos • cd-roms of related interest